Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer

The maximal tolerated dose for gemcitabine given once weekly with concurrent hypofractionated conformal bladder radiotherapy was 150 mg/m2, with a maximal recommended dose of 100 mg/m2. This dose regimen has now entered Phase II clinical trials.